There are many reasons why people choose to work for contract research organisations (CROs). These are organisations which sell services to aid biotech companies and pharmaceutical firms in making products, and can offer a hugely varied and rewarding working environment.
Scientists working for CROs will often jump between projects, spending anything from a fortnight to two years on different work. This is a major advantage for many people who seek a career that continually presents new challenges and opportunities, one where days can change considerably from week to week.
Problem Solving Satisfaction
Another major upside for many people who choose a CRO career path is the satisfaction that can be achieved through service orientation and the pride that can come from offering particular skills and flexibility. Solving a particular problem for a client can be extremely rewarding, especially when it is clear that they would not have the skills required to achieve a similar result.
There is also the added benefit of changes to the pharmaceutical industry boosting research capabilities within CROs. Clinical solutions providers such as http://www.gandlscientific.com/ have noticed an increase in the number of jobs available, along with a rise in the complexity and quality of the work as more jobs and tasks are outsourced. This means more potential opportunities for people working within the sector.
There was a time when CROs typically carried out repetitive and boring lab work, along with low-priority projects, but times have changed and workers within the field are now continually engaged with the R&D process, starting with the discovery of drugs and leading to clinical trials and more.
Increased Opportunities
This is one of the reasons why healthy growth is being experienced within the sector. Tufts University School of Medicine’s Center for the Study of Drug Development, for example, revealed an average seven per cent annual rise in global opportunities with CROs, meaning a doubling of R&D jobs in a decade.
A GBI Research report, meanwhile, showed that the worldwide R&D outsourcing marketplace accounted for around 25 per cent of R&D expenditures for pharmaceutical companies during 2010, and this figure is expected to have risen to 37.1 per cent by 2018.
The varied work on offer from CROs is made possible as the sector increasingly fills gaps in the capacity of biotech and pharma companies.